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symmetry-related sites or triplets, suggesting that each triplet consti-
tutes an evolutionary unit. Based on evolutionary selection, 111
structural sites (37 triplets) were found to be important. These sites
play a key role in structure/function of MCs being involved in
conformational changes (sites of the gates, Pro–Gly levels, and aromatic
belts) or in the substrate speciﬁcity (sites of the substrate-binding area
in between the two gates)[3,4,5]. Furthermore, the evolutionary
pressure analysis revealed that the matrix short helix sites underwent
different degrees of selection with high inter-paralog variability.
Evidence is presented that these sites form a new sequence motif in a
subset ofMCs and play a regulatory function by interactingwith ligands
and/or proteins of the mitochondrial matrix [3].
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In mammals, protein methylation is a post-translational modiﬁca-
tion that regulates cellular processes, but little is known about either its
extent or role in mitochondria. As part of a systematic investigation of
protein methylation in the organelle, we identiﬁed 38 putative
mitochondrial protein methylases by bioinformatic analysis, including
the methyltransferase-like protein 20 (METTL20). We established that
METTL20 is a bona ﬁde human mitochondrial protein, and showed by
stable isotope labeling by amino acids in cell culture (SILAC) and mass
spectrometry, that METTL20 binds to the electron transfer ﬂavoprotein
(ETF) and trimethylates lysine residues 199 and 202 on its β-subunit
(ETFβ). The ETF is a heterodimeric complex of α- and β-subunits and it
serves as a mobile electron carrier linking fatty acid oxidation and one-
carbon metabolism to the ubiquinone pool in the inner mitochondrial
membrane. The methylated lysine residues 199 and 202 are immedi-
ately adjacent to a ‘recognition loop’, which promotes the interaction of
ETFβwith up to 11 different acyl-CoA dehydrogenases in order to allow
electron transfer to occur. Suppression of methylation of ETFβ in mouse
C2C12 cells that are oxidizingpalmitate as an energy source reduced the
consumption of oxygen by the cells. These experiments suggest that the
trimethylation of lysine residues 199 and 202may regulate interactions
between the reduced dehydrogenases and ETFβ, and thereby the ﬂow
of electrons from fatty acid oxidation to the mitochondrial respiratory
chain. METTL20 is the ﬁrst protein lysine methyltransferase to be
associated with mammalian mitochondria. Earlier we identiﬁed
NDUFAF7 as the ﬁrst protein arginine methyltransferase in human
mitochondria [1].
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The mitochondrial permeability transition pore (mPTP) is the key
mediator of ischaemia reperfusion injury in the heart and its pharma-
cological inhibition provides cardioprotection [1]. The exact molecular
composition of the mPTP remains uncertain, although a facilitating role
of cyclophilin D in mPTP opening is established and evidence has been
presented for an involvement of the adenine nucleotide translocase
(ANT), the phosphate carrier (PiC) and most recently the F1F0-ATPase
[1,2]. Here we characterise the inhibition of the mPTP by a novel and
potent inhibitor developed by Congenia (GNX-B) to provide further
insights into the molecular identity of the pore. Using light scattering
assays of mPTP opening we demonstrate that GNX-B binds only to the
active form of the mPTP with a Ki of about 2 nM. Furthermore, because
the inhibitor binding is very tight we were able to calculate the number
of binding sites which were found to increase or decrease in response to
agents that caused mPTP activation (e.g. KSCN and phenylarsine oxide)
or inhibition (e.g. ADP and bongrekic acid) respectively. Calculated
values for mPTP binding sites ranged from 7–22 pmol per mg protein
depending on the degree of activation or inhibition which is more than
an order of magnitude less that the amount of the ANT, PiC or ATPase
present in mitochondria. These data suggest that formation of the mPTP
does not involve any of these proteins in their native state but is
consistent with our previous suggestion that the pore may form from a
small fraction of such proteins when they enter a “distorted”
conformation in response to mPTP activating conditions. We have also
shown that the number of GNX-B binding sites is increased as the
concentration of Ca2+ used to induce mPTP opening is increased.
However, if calcium was added prior to GNXB and then pore opening
initiated by addition of polyethylene glycol (PEG) to shrink pre-swollen
mitochondria, the ability of GNXB to inhibit mPTP opening was
impaired. These data suggest that the inhibitor must bind before mPTP
opening is triggered by Ca2+ if it is to be effective.
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